Alliance for Pandemic Preparedness

April 8, 2021

CERC-002 a Human Anti-LIGHT mAb Reduces Respiratory Failure and Death in Hospitalized COVID-19 ARDS Patients

Category:

Topic:

Keywords (Tags):

  • [Pre-print, not peer-reviewed] The monoclonal antibody (mAb) treatment CERC-002 reduced mortality and the risk of respiratory failure through day 28 compared to placebo (84% vs 65%; p=0.044) among hospitalized COVID-19 patients with mild-to-moderate acute respiratory distress syndrome (ARDS) according to a randomized placebo-controlled study (n=83). Efficacy was highest among patients ≥60 years old (77% vs 47%; p=0.042).

Perlin et al. (Apr 7, 2021). CERC-002 a Human Anti-LIGHT mAb Reduces Respiratory Failure and Death in Hospitalized COVID-19 ARDS Patients. Pre-print downloaded Apr 8 from https://doi.org/10.1101/2021.04.03.21254748